Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/engBCfbwocfElGgJbTwZ

March 13, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
Boehringer Ingelheim BioXcellence™ makes outsourcing easy
As a leading biopharmaceutical contract manufacturer Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA). Explore BI BioXcellence™
  Health Care & Policy 
 
  • New U.S. stockpile of smallpox drug ignites debate
    The U.S. government's purchase of $463 million worth of smallpox drug Arestvyr in preparation for a bioterrorism attack has drawn criticism from some bioweapons experts, who say it is excessive given the current stockpile of smallpox vaccine. Siga Technologies President Eric Rose said that the 2 million supplies of its drug Arestvyr "is on the low end" considering that "smallpox is just as contagious and has 30 times the mortality" of the influenza virus. One biosecurity expert said high prices are needed to induce companies to make drugs that may have no use in routine health care. The New York Times (tiered subscription model) (3/12) LinkedInFacebookTwitterEmail this Story
  • Biotech rookie, wild card and comeback players of the year
    Alnylam Pharmaceuticals is Luke Timmerman's pick for comeback player of 2013 after settling early disputes and forging ahead with RNA interference drugs. Ironwood Pharmaceuticals is a wild card as it awaits market response to its irritable bowel syndrome drug, and Hyperion Therapeutics is living up to early promise to become rookie of the year, Timmerman writes. He picks Alkermes for "steal of the draft" award and Clay Siegall of Seattle Genetics for manager of the year. Xconomy (3/11) LinkedInFacebookTwitterEmail this Story
 
  • Biogen submits hemophilia A drug for FDA approval
    Biogen Idec has filed a biologics license application with the FDA for approval to use recombinant factor VIII Fc fusion protein as a treatment for hemophilia A. The drug belongs to a new class of long-lasting clotting factor treatments. The application was based on positive results of the late-stage A-LONG trial. RTT News (3/12) LinkedInFacebookTwitterEmail this Story
  • Pfizer halts development of hep C drug filibuvir
    Pfizer said it would stop developing its midstage hepatitis C drug filibuvir, or PF-00868554. Potential competitors included new hepatitis C therapies from Gilead Sciences and AbbVie. "We continue to prioritize our [research and development] capital allocation to drive the next wave of innovative medicines and vaccines that bring benefit to patients and value to health care systems around the world," Pfizer's Victoria Davis said. Pharmaceutical Business Review Online (3/11) LinkedInFacebookTwitterEmail this Story
The New You Starts Here.
Designed for busy healthcare professionals, FIU's online Healthcare MBA is transformative. Graduates emerge ready for a leadership role in healthcare, with a clear vision of how to lead collaboratively and advance the business of healthcare. Classes begin Fall 2015. Start here.

  Company & Financial News 
 
  • Shire bolsters rare disease pipeline with Premacure buy
    Shire has acquired Swedish biotech firm Premacure. Premacure is developing a protein replacement therapy for prevention of retinopathy of prematurity, a potentially blinding eye disease in premature babies. The acquisition is expected to strengthen Shire's rare disease drug business and extend its product offerings into neonatology. Reuters (3/12) LinkedInFacebookTwitterEmail this Story
Don't lose access to your customer's facility. We can help.
Rep-Clear: Watermark's Solution for ensuring access to your customers. Rep-Clear includes our proprietary platform for tracking all items associated with a Rep and our professional support staff to provide individual service, ensuring all items are up to date and access to a facility is not lost. View common rep excuses.

  Global Developments 
  • U.K.'s Biomedical Catalyst fund announces 2nd-round grants
    Fifty-one biomedical firms will share more than $70 million in a second round of grants from the U.K.'s Biomedical Catalyst fund to help move life sciences projects through the "valley of death." Twenty-five feasibility studies, 18 early-stage projects and eight late-stage projects received awards. The fund has encouraged more private-sector investment in U.K. biotech companies, allowing them to grow faster and engage in more research, according to a BioIndustry Association report. PharmaTimes (U.K.) (3/12) LinkedInFacebookTwitterEmail this Story
How Much Do You Really Need to Make? The Answer May Shock You
Rather than focus on what you can afford to pull out of the business to cover your living expenses, you need to focus on how much you need to earn at your business in order to afford the lifestyle you want to have. This is where the Personal Earnings Goal, or PEG, comes into play. Learn how to calculate your PEG and find out how much you really need to make.

  Food & Agriculture 
 
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Industrial & Environmental 
  • Report: Cellulosic ethanol cost could match corn by 2016
    A survey of 11 of the biggest cellulosic ethanol companies by Bloomberg New Energy Finance says that cellulosic ethanol production could become price competitive with corn-based ethanol by 2016. "If our survey proves accurate, cellulosic ethanol will make meaningful inroads into the vehicle-fuel market during the last years of this decade," said Harry Boyle of BNEF. Bloomberg (3/12) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
Humor is an affirmation of dignity, a declaration of man's superiority to all that befalls him."
--Romain Gary,
French diplomat, novelist, film director and aviator


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information